Session Information
AABB Annual Meeting and CTTXPO 2013
Click here to go to the previous page
Current Impact of Non-ABO-Related Hemolytic Transfusion Reactions
Track : TC - Technical/Clinical
Program Code: 9420-TC
Date: Tuesday, October 15, 2013
Time: 2:00 PM to 3:30 PM  EST
Location: 301-303
DIRECTOR :
Gregory Denomme, PhD, FCSMLS(D), Director of Immunohematology & Transfusion Services, BloodCenter of Wisconsin
MODERATOR :
Bill Flegel, MD, Chief, Laboratory Services Section, National Institutes of Health
SPEAKER (S):
Dr. Sally Campbell-Lee, MD, Director, Transfusion Medicine, University of Illinois at Chicago
Recognizing Hemolysis, Reacting to Trouble, Finding New Approaches
S. Gerald Sandler, MD, Director, Transfusion Medicine/Professor of Medicine and Pathology, MedStar Georgetown University Hospital
Incidence of Non-ABO Hemolytic Transfusion Reactions What is Hemovigilience Telling Us?
Gary Stack, MD, PhD, Chief, Pathology and Laboratory Medicine Service, VA Connecticut Healthcare System
Antibody Persistence and Evanescence
Description
Hemovigilance programs have been launched by several countries to address the noninfectious hazards of transfusion. Of particular interest is the prevention of hemolytic transfusion reactions. Matching blood transfusion to the transfusion recipient antigen profile has been a long-standing therapy to address and further prevent red cell alloimmunization. Last year we learned of the comorbidities associated with delayed hemolytic transfusion reactions and that as many as 80% of alloimmune responses become undetectable by the next transfusion. What can be done to address red cell alloimmunization? This education session is designed to challenge physicians and laboratorians to think about broad-based ways to mitigate immune hazards of transfusion: alloantibody registries, antigen-negative blood and genotype dry matching of red cells including the use of historical antigen typings all play a role. Come to this session for a review of the clinical impact of hemolytic transfusion reactions and importance of alloantibody detection in the chronic transfusion recipient, the advantages of historical red cells phenotypes/genotypes on the delivery of safe blood products for transfusion and the impact of a hemovigilance program.

Gary Stack did not consent to be recorded.

  • Evaluate the signs of non-ABO hemolytic reactions, how to report them and future options to curtail these adverse events.
  • Provide hemovigilance data on the incidence and patient impact of non-ABO-related hemolytic transfusion reactions.
  • Summarize red cell alloimmunization and antibody evanescence rates.


CE CategoryCE Value
California Clinical Laboratory Personnel 1.5
California Nurse 1.8
Florida Laboratory Personnel 1.8
General Attendee 1.5
Physician 1.5
Please note: Continuing education (CE) credit is available for online offerings only. Individuals that purchase CD-ROMs will not receive CE credit for the programs they view.


Audio Synchronized to PowerPoint
(Code: 9420-TCAM/9420-TCA/9420-TCM/9420-TC)
Annual Meeting Attendee/AABB Member:$25 USD
Annual Meeting Attendee/Non AABB Member:$40 USD
Non-Attendee/AABB Member:$40 USD
Non-Attendee/Non AABB Member $50 USD - Your Price
Add to Shopping Cart
This session is a part of:
Copyright © 2014 by MultiView, Inc. All website graphics, text, design, software, and other works are
the copyrighted works of MultiView, Inc. All audio, video, presentation materials, logos and text
are the copyrighted works of their respective owners. All Rights Reserved. Any redistribution or
reproduction of any materials herein is strictly prohibited.